LEGN

Legend BiotechC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$42.00

+16.7% vs current

Most likely

Base case

45%

Probability

Target price

$28.00

-22.2% vs current

B-

Bear case

30%

Probability

Target price

$14.00

-61.1% vs current

AI sentiment snapshot

Latest data as of 2026-04-30

AI commentary

Primary-source tone turned more constructive after the March 10, 2026 results and the April 28, 2026 scheduling notice for Q1 results, but this is still a cautious monitoring setup because the packet began with no primary notes, no analyst-revision breadth, and very high uncertainty. Medium headline buzz is supported by earnings, CARVYKTI data presentations, and the upcoming May 12 report, yet the stock's large discount to the packet's median target suggests investors are still demanding proof that manufacturing expansion, safety management, and operating-profit timing will hold.

RankAlpha Sentiment Codex - 2026-04-30

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-12catalystQ1 2026 results on May 12 will test whether the profitability path is holdingHigh impact

Legend Biotech said it will report first-quarter 2026 results on May 12, 2026. After the March 10 update showed CARVYKTI franchise profitability in 2025 and management's beyond-2026 runway view, the next print is the cleanest near-term check on CARVYKTI demand, community-site expansion, and operating leverage cadence. [#PR-2026-04-28] [#PR-2026-03-10]

2026-06-30catalystManufacturing and site expansion could unlock more CARVYKTI volumeHigh impact

Primary company updates point to a tangible capacity story rather than a generic pipeline hope: Q4 2025 results said CARVYKTI was available across 294 sites in 14 markets and that the expanded Raritan facility could support up to 10,000 patients annually, while the Q3 2025 release said Tech Lane commercial production in Belgium would begin supporting additional global demand in the first half of 2026. If those supply additions translate into faster treatment starts, revenue upside can continue. [#PR-2026-03-10] [#PR-2025-11-12]

2026-12-31catalystEarlier-line CARVYKTI evidence may deepen adoption, but safety remains part of the debateHigh impact

Legend's January 21 Tandem release highlighted six posters on efficacy, safety, and real-world outcomes and argued outcomes are especially compelling when CARVYKTI is used earlier in treatment, while the November 2025 update said FDA and EC label updates added overall-survival data from CARTITUDE-4. That supports a longer adoption runway, but the same company materials also emphasize serious safety risks and updated enterocolitis warnings, so the setup is positive but not de-risked. [#PR-2026-01-21] [#PR-2025-11-12]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-30 • Updated nightlySource: Internal modelMethodology